DK0928335T3 - Fremgangsmåde til anvendelse af oligonukleotider med modificerede CpG-dinukleosider - Google Patents

Fremgangsmåde til anvendelse af oligonukleotider med modificerede CpG-dinukleosider

Info

Publication number
DK0928335T3
DK0928335T3 DK97941505T DK97941505T DK0928335T3 DK 0928335 T3 DK0928335 T3 DK 0928335T3 DK 97941505 T DK97941505 T DK 97941505T DK 97941505 T DK97941505 T DK 97941505T DK 0928335 T3 DK0928335 T3 DK 0928335T3
Authority
DK
Denmark
Prior art keywords
oligonucleotides
gene expression
modified
cpg
modified cpg
Prior art date
Application number
DK97941505T
Other languages
Danish (da)
English (en)
Inventor
Sudhir Agrawal
Original Assignee
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybridon Inc filed Critical Hybridon Inc
Application granted granted Critical
Publication of DK0928335T3 publication Critical patent/DK0928335T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/311—Phosphotriesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK97941505T 1996-09-10 1997-09-10 Fremgangsmåde til anvendelse af oligonukleotider med modificerede CpG-dinukleosider DK0928335T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/711,568 US5856462A (en) 1996-09-10 1996-09-10 Oligonucleotides having modified CpG dinucleosides
PCT/US1997/016017 WO1998011211A2 (en) 1996-09-10 1997-09-10 METHOD FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES

Publications (1)

Publication Number Publication Date
DK0928335T3 true DK0928335T3 (da) 2003-06-16

Family

ID=24858610

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97941505T DK0928335T3 (da) 1996-09-10 1997-09-10 Fremgangsmåde til anvendelse af oligonukleotider med modificerede CpG-dinukleosider

Country Status (11)

Country Link
US (1) US5856462A (https=)
EP (1) EP0928335B1 (https=)
JP (1) JP5265067B2 (https=)
AT (1) ATE236248T1 (https=)
AU (1) AU4339997A (https=)
CA (1) CA2265917C (https=)
DE (1) DE69720481T2 (https=)
DK (1) DK0928335T3 (https=)
ES (1) ES2190541T3 (https=)
PT (1) PT928335E (https=)
WO (1) WO1998011211A2 (https=)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6825174B2 (en) 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
US7034007B1 (en) 1995-06-07 2006-04-25 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6238921B1 (en) * 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
JP2002514397A (ja) * 1998-05-14 2002-05-21 コーリー ファーマシューティカル ゲーエムベーハー ＣｐＧオリゴヌクレオチドを用いる造血調節の方法
HK1042706A1 (zh) * 1998-08-03 2002-08-23 东卡罗来纳大学 低腺苷反义寡核苷酸制剂、组合物、试剂盒及处理
EP1109924A2 (en) * 1998-09-09 2001-06-27 Genzyme Corporation Methylation of plasmid vectors
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6214986B1 (en) * 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression
US6172216B1 (en) * 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
US5977341A (en) * 1998-11-20 1999-11-02 Isis Pharmaceuticals Inc. Antisense modulation of inhibitor-kappa B kinase-beta expression
US5962673A (en) * 1998-11-20 1999-10-05 Isis Pharmaceuticals Inc. Antisense modulation of inhibitor-kappa B kinase-alpha expression
US5959097A (en) * 1998-11-20 1999-09-28 Isis Pharmaceuticals, Inc. Antisense modulation of MEK2 expression
US5981732A (en) * 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US7083796B2 (en) 2000-06-20 2006-08-01 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US20040171566A1 (en) * 1999-04-06 2004-09-02 Monia Brett P. Antisense modulation of p38 mitogen activated protein kinase expression
US6140124A (en) * 1999-04-06 2000-10-31 Isis Pharmaceuticals Inc. Antisense modulation of P38 mitogen activated protein kinase expression
BR0006019A (pt) * 1999-04-06 2001-03-13 Univ East Carolina Oligonucleotìdeo de anti-sentido de adenosina baixo, composições, kit & método para tratamento de distúrbios de vias aéreas associados com broncoconstricção, inflamação pulmonar, alergia(s) & depleção de surfactante
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US6013788A (en) * 1999-04-09 2000-01-11 Isis Pharmaceuticals Inc. Antisense modulation of Smad3 expression
US6046321A (en) * 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
DE19935756A1 (de) * 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
EP1496121A3 (en) * 1999-08-13 2005-02-09 Hybridon, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
EP2314693A3 (en) * 1999-08-13 2012-11-28 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
EP1229931A4 (en) * 1999-10-07 2003-05-28 Corixa Corp FUSION PROTEINS FROM MYCOBACTERIUM TUBERCULOSIS
CA2291367A1 (en) * 1999-12-06 2001-06-06 Isabelle Henry Genetic constructions having a reduced or an increased number of epigenetic control regions and methods of use thereof
AU2001227889A1 (en) 2000-01-14 2001-07-24 The United States of America, represented by The Secretary, Department of Health & Human Services Oligodeoxynucleotide and its use to induce an immune response
IL151097A0 (en) 2000-02-23 2003-04-10 Smithkline Beecham Biolog Tumour-specific animal proteins
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20040006036A1 (en) * 2000-04-12 2004-01-08 Gmr, A Delaware Corporation Silencing transcription by methylation
HU230847B1 (en) 2000-05-19 2018-08-28 Corixa Corp Prophylactic and therapeutic treatment of infectious and other diseases with mono and disaccharide-based compounds
AR029540A1 (es) 2000-06-28 2003-07-02 Corixa Corp COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
AU2001294750C1 (en) * 2000-09-26 2008-09-18 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
ES2307568T3 (es) * 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
US7105495B2 (en) * 2001-04-30 2006-09-12 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
JP2005504513A (ja) 2001-05-09 2005-02-17 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
US7785610B2 (en) * 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
EP2423335B1 (en) * 2001-06-21 2014-05-14 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
WO2003020884A2 (en) 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
JP4319908B2 (ja) 2001-08-24 2009-08-26 ユニバーシティ オブ ビクトリア イノベーション アンド ディベロップメント コーポレーション プロテアーゼ活性化配列を含むプロアエロリシンおよび前立腺癌の治療のための使用方法
MXPA04002631A (es) * 2001-09-20 2004-07-08 Glaxo Group Ltd Vacunas de adn optimizadas por codon gag-vih.
WO2003027313A2 (en) 2001-09-24 2003-04-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
WO2003035836A2 (en) * 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
EP1456380B1 (en) * 2001-11-02 2012-04-18 Giuliani International Limited Smad7 inhibitors for the treatment of cns diseases
DK2224012T3 (da) 2001-12-17 2013-05-13 Corixa Corp Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
WO2003054161A2 (en) 2001-12-20 2003-07-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
WO2003066649A1 (en) * 2002-02-04 2003-08-14 Biomira Inc. Immunostimulatory, covalently lipidated oligonucleotides
US7026465B2 (en) * 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
EP1575504A4 (en) 2002-08-01 2009-11-04 Us Gov Health & Human Serv METHOD FOR THE TREATMENT OF INFLAMMATORY ARTHROPATHIES WITH SUPPRESSORS OF THE CPG OLIGONUCLEOTIDES
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
US8043622B2 (en) 2002-10-08 2011-10-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
CN101863930A (zh) 2003-01-06 2010-10-20 科里克萨有限公司 一些氨烷基氨基葡糖苷磷酸酯化合物和它们的用途
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US7354907B2 (en) * 2003-02-07 2008-04-08 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
AU2004226605A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
AU2004275876B2 (en) 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
EP1678303A2 (en) * 2003-10-30 2006-07-12 Coley Pharmaceutical GmbH C-class oligonucleotide analogs with enhanced immunostimulatory potency
CN1989439B (zh) 2004-05-06 2010-12-29 美国政府健康及人类服务部 治疗葡萄膜炎的方法以及组合物
EP2497831B1 (en) 2004-05-25 2014-07-16 Oregon Health and Science University TB vaccination using HCMV-based vaccine vectors
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
WO2006065751A2 (en) 2004-12-13 2006-06-22 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
WO2006104890A2 (en) 2005-03-31 2006-10-05 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
DK2457926T3 (da) 2005-04-29 2015-01-05 Glaxosmithkline Biolog Sa Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
ATE502954T1 (de) 2005-06-14 2011-04-15 Protox Therapeutics Inc Verfahren zur behandlung oder prävention gutartiger prostatahyperplasie unter verwendung modifizierter porenbildender proteine
PT2078080E (pt) 2006-09-27 2015-09-18 Coley Pharm Gmbh Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
BRPI0809926B8 (pt) * 2007-04-04 2021-05-25 Infectious Disease Res Inst composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
DK2170384T3 (en) 2007-07-02 2016-07-25 Etubics Corp METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
CN101888856B (zh) 2007-11-07 2014-08-27 塞尔德克斯医疗公司 结合人树突和上皮细胞205(dec-205)的抗体
JP5711972B2 (ja) 2007-12-24 2015-05-07 アイディー バイオメディカル コーポレイション オブ ケベック 組換えｒｓｖ抗原
WO2009143292A2 (en) 2008-05-21 2009-11-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating pneumoconiosis with oligodeoxynucleotides
AU2009323996A1 (en) 2008-12-03 2011-07-07 Institut Pasteur Use of phenol-soluble modulins for vaccine development
HUE028085T2 (en) 2009-06-24 2016-11-28 Glaxosmithkline Biologicals Sa Recombinant RSV antigens
EP2445527A2 (en) 2009-06-24 2012-05-02 ID Biomedical Corporation of Quebec Vaccine
CA2768186A1 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
WO2011101332A1 (en) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
EA201690310A1 (ru) 2010-04-13 2016-12-30 Селлдекс Терапьютикс Инк. Антитела, связывающие cd27 человека, и их применение
US20130345079A1 (en) 2010-10-27 2013-12-26 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
EP2637687B1 (en) 2010-11-08 2021-01-06 Infectious Disease Research Institute Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
CA2835644C (en) 2011-05-13 2021-06-15 Novartis Ag Pre-fusion rsv f antigens
CA2837651A1 (en) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
HUE065746T2 (hu) 2012-08-03 2024-06-28 Access To Advanced Health Inst Készítmények és eljárások aktív mycobacterium tuberculosis fertõzés kezelésére
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
EP2970398B1 (en) 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
BE1022174B1 (fr) 2013-03-15 2016-02-24 Glaxosmithkline Biologicals S.A. Vaccin
EP2978447B1 (en) 2013-03-28 2019-05-08 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
MX2016001695A (es) 2013-08-05 2016-05-02 Glaxosmithkline Biolog Sa Composiciones inmunogenas de combinacion.
EP2952893A1 (en) 2014-06-04 2015-12-09 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Method for detecting antibody-secreting B cells specific for HLA
MX384992B (es) 2014-06-13 2025-03-14 Glaxosmithkline Biologicals Sa Combinaciones inmunógenas.
AU2015252119A1 (en) 2014-11-07 2016-05-26 Takeda Vaccines, Inc. Hand, foot, and mouth vaccines and methods of manufacture and use thereof
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
WO2016097865A1 (en) 2014-12-19 2016-06-23 Regenesance B.V. Antibodies that bind human c6 and uses thereof
CN107406857B (zh) 2015-01-09 2021-06-29 埃图比克斯公司 用于联合免疫治疗的方法和组合物
AU2015384786B2 (en) 2015-03-03 2020-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Display platform from bacterial spore coat proteins
WO2016145085A2 (en) 2015-03-09 2016-09-15 Celldex Therapeutics, Inc. Cd27 agonists
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
CA2986961C (en) 2015-05-26 2023-07-25 Ohio State Innovation Foundation Nanoparticle based vaccine strategy against swine influenza virus
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
US12297266B2 (en) 2016-04-18 2025-05-13 Celldex Therapeutics, Inc. Agonistic antibodies that bind human CD40 and uses thereof
JP2019521095A (ja) 2016-05-21 2019-07-25 インフェクシャス ディズィーズ リサーチ インスティチュート 二次性結核および非結核性マイコバクテリウム感染症を治療するための組成物および方法
CN109890408A (zh) 2016-05-27 2019-06-14 埃特彼塞斯公司 新表位疫苗组合物及其使用方法
BR112019004913B1 (pt) 2016-09-16 2022-07-12 Infectious Disease Research Institute Vacinas que compreendem polipeptídeos de mycobacterium leprae para a prevenção, tratamento e diagnóstico de lepra
US11084850B2 (en) 2016-12-16 2021-08-10 The Pirbright Institute Recombinant prefusion RSV F proteins and uses thereof
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
WO2018193063A2 (en) 2017-04-19 2018-10-25 Institute For Research In Biomedicine Novel malaria vaccines and antibodies binding to plasmodium sporozoites
MX2019015076A (es) 2017-06-15 2020-08-03 Infectious Disease Res Inst Portadores lípidos nanoestructurados y emulsiones estables y usos de los mismos.
US11123415B2 (en) 2017-08-16 2021-09-21 Ohio State Innovation Foundation Nanoparticle compositions for Salmonella vaccines
KR20200117981A (ko) 2017-11-03 2020-10-14 다케다 백신즈 인코포레이티드 지카 백신 및 면역원성 조성물, 그리고 이를 이용하는 방법들
EP3743102A1 (en) 2018-01-26 2020-12-02 Nantcell, Inc. Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
JP7576835B2 (ja) 2018-03-22 2024-11-01 ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム 自己免疫疾患および癌を治療するための可溶性インターロイキン７受容体（ｓＩＬ７Ｒ）調節療法
CA3097369A1 (en) 2018-04-17 2019-10-24 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
WO2022051022A1 (en) 2020-09-04 2022-03-10 Infectious Disease Research Institute Co-lyophilized rna and nanostructured lipid carrier
CA3214853A1 (en) 2021-04-09 2022-10-13 Celidex Therapeutics, Inc. Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
CN118510790A (zh) 2021-12-13 2024-08-16 美国政府(由卫生和人类服务部的部长所代表) 噬菌体λ-疫苗系统
CA3266697A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute COMPOSITION OF AN IMMUNOGENEOUS VACCINE CONTAINING A SAPONIN
KR20250167153A (ko) 2023-03-03 2025-11-28 셀덱스 쎄라퓨틱스, 인크. 항-줄기 세포 인자(scf) 및 항-흉선 기질 림포포이에틴(tslp) 항체, 및 이중특이적 구축물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194428A (en) * 1986-05-23 1993-03-16 Worcester Foundation For Experimental Biology Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5149797A (en) * 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
DE4200433A1 (de) * 1992-01-10 1993-07-15 Otto Hofstetter Verfahren zur herstellung von stabilen fluessigen parfuemrohstoffmischungen mit hohem feststoffgehalt
US5652355A (en) * 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
WO1994026877A1 (en) * 1993-05-17 1994-11-24 The Regents Of The University Of California Ribozyme gene therapy for hiv infection and aids
WO1995009236A1 (en) * 1993-09-28 1995-04-06 The General Hospital Corporation USING ANTISENSE OLIGONUCLEOTIDES TO MODULATE NERVE GROWTH AND TO REVERSE β/A4 AMYLOID-INDUCED MORPHOLOGY
EP1167379A3 (en) * 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
CN1175281A (zh) * 1994-12-22 1998-03-04 海布里登公司 立体特异性硫代磷酸寡核苷酸的合成

Also Published As

Publication number Publication date
AU4339997A (en) 1998-04-02
WO1998011211A3 (en) 1998-04-16
US5856462A (en) 1999-01-05
WO1998011211A2 (en) 1998-03-19
ES2190541T3 (es) 2003-08-01
DE69720481D1 (de) 2003-05-08
ATE236248T1 (de) 2003-04-15
EP0928335B1 (en) 2003-04-02
DE69720481T2 (de) 2004-02-12
JP5265067B2 (ja) 2013-08-14
CA2265917A1 (en) 1998-03-19
JP2001500511A (ja) 2001-01-16
EP0928335A2 (en) 1999-07-14
PT928335E (pt) 2003-07-31
CA2265917C (en) 2008-07-08

Similar Documents

Publication Publication Date Title
DK0928335T3 (da) Fremgangsmåde til anvendelse af oligonukleotider med modificerede CpG-dinukleosider
EP1325019A4 (en) ANTISENSE MODULATION OF CLUSTERINEXPRESSION
DK0677056T3 (da) Oligonukleotid-alkylphosphonater og -alkylphosphonothioater
DK1019428T3 (da) Inverterede kimæriske og hybride oligonucleotider
NO20014058D0 (no) TRPM-2 antisense-terapi
WO1996023065A3 (en) Inhibition of neovascularization using vegf-specific oligonucleotides
DE60024660D1 (de) Menschliche rnase h und entsprechende oligonukleotidverbindungen
ATE216705T1 (de) Antisense-oligonukleotidmodulation der raf- genexpression
EP1165594A4 (en) ANTISENS OLIGONUCLEOTIDE MODULATION OF THE STAT3 EXPRESSION
EP1248794A4 (en) ANTISENS MODULATION OF THE SMAD7 EXPRESSION
PT1117672E (pt) Modulação anti-sentido da expressão de survivina
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
EP1123414A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF INTEGRIN ALPHA 4
BR0008788A (pt) Sequencias anti-sentido antitumor dirigidas contra componentes r1 e r2 de ribonucleotìdeo reductase
MY134778A (en) Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization
EP1131107A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF INHIBITOR-KAPPA-B-KINASE-ALPHA
EP1131332A4 (en) ANTISENSE MODULATION OF THE INHIBITOR KAPPA B KINASE-BETA EXPRESSION
EP1250347A4 (en) ANTISENSE MODULATION OF THE AKT-3 EXPRESSION
DE69625919D1 (de) Verwendung von zyklodextrine zur modulierten genexpression mit reduzierter immunostimulation
EP0747386A3 (en) Method and antisense oligonucleotides to Interleukin-6 receptor mRNA for inhibiting cellular proliferation
WO2002040637A3 (en) Antisense modulation of pi3k p85 expression
UA30460A (uk) Спосіб лікування системного аутоімунного захворювання
UA36385A (uk) Спосіб лікування генералізованого пародонтиту